Articles

Why this Treasury market trade continues to draw scrutiny

Inside the $26 trillion Treasury market, a particular trade continues to draw scrutiny ahead of year-end.

‘Santa Claus’ rally time for stock market? Why investors should dial back their expectations for this seasonal year-end gift.

Wall Street is eagerly waiting for the so-called Santa Claus rally to further fuel stock-market gains that have already put investors in a holiday mood.

Novo Nordisk, FDA warn of fake Ozempic

The FDA has seized thousands of units of fake Ozempic, the agency said Thursday.

More people fell behind on credit card bills this year. Here’s how rough it could get in 2024.

Things could get worse before they get better.

The inflation challenge of 2024

Post Content

U.S. threatens penalties against foreign banks helping Russia evade Ukraine war sanctions

Post Content

Biotech stocks set for a rebound in 2024, analysts say

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

Spain’s centuries-old ‘El Gordo’ lottery is handing out nearly $2.9 billion in winnings this year

“The Fat One” gets its name from its status as one of the richest lotteries in the world.

13 stocks that are down for 2023 but may bounce back in 2024 or beyond

John Buckingham of the Prudent Speculator takes a hard look at opportunities brought about by the stock market's focus on short-term developments

For savers, the end of 2023 is different: How new rules can help you sock away even more

Don't leave money on the table because the rules have changed. Here's how to max out 2023 retirement contributions, and how to save even more in 2024

U.S. durable-goods orders rebound in November by most since July 2020

Orders for durable goods rose jumped 5.4% in November, the government said Friday. This is the largest gain since July 2020. It is the second gain in the past three months.

Karuna Therapeutics’ stock hits record territory after Bristol Myers’ $14 billion buyout deal

Karuna Therapeutics stock jumped 48% into record territory early Friday, after the biopharmaceutical company announced a $14 billion agreement to be bought by Bristol Myers Squibb.
1 879 880 881 882 883 1,563